APLN and prostate cancer: Consistently, analyses of the Oncomine database and GEPIA tool, as well as IHC data from the tissue array, confirmed significantly upregulated apelin expression in prostate cancer samples (Figure 1C–E) and higher levels of apelin were negatively associated with survival (Figure 1F).